Eosinophilic chronic rhinosinusitis as a predictor of super-responder and clinical remission in patients with uncontrolled type 2-high severe asthma treated with biologics
- 13 February 2025
- journal article
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (3) , 247-251
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science (22K16169)
- Teijin Pharma
This publication has 12 references indexed in Scilit:
- Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2024
- Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic TherapiesChest, 2023
- Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patientRespiratory Medicine, 2023
- Biologics for severe asthma—Which, when and why?Respirology, 2023
- Defining a Severe Asthma Super-Responder: Findings from a Delphi ProcessThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Cycling therapy with benralizumab and dupilumab for severe eosinophilic asthma with eosinophilic chronic rhinosinusitis and eosinophilic otitis mediaAllergology International, 2021
- Impact of sinus surgery on type 2 airway and systemic inflammation in asthmaJournal of Asthma, 2020
- Radiographic Evidence of Sinonasal Inflammation in Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: An Underrecognized AssociationThe Journal of Allergy and Clinical Immunology: In Practice, 2017
- Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC StudyAllergy, 2015
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012